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Abstract We have characterized the effect of angiotensin con- 
verting enzyme (ACE) inhibitors on the activity of CuZn-snper- 
oxide dismntase (CuZn-SOD), Mn-snperoxide dismutase (Mn- 
SOD), catalase, and selenium-dependent glutathione peroxidase 
(Se-GPx). CF1 mice (4-month-old females) were administered 
water containing enalapril (20 rag/l) or captopril (50 rag/I), during 
4 to 11 weeks. After 11 weeks, enalapril treatment caused an 
increase in the activity of CuZn-SOD, Mn-SOD and Se-GPx, 
from 19 -+ 4 to 46 +- 7, 2.1 -+ 0.2 to 3.8 -- 0.2 units/mg protein and 
27--3 to 54- -3  milliunits/mg protein, respectively. After 11 
weeks, captopril treatment increased the activities (P < 0.05) of 
CuZn-SOD, MnSOD and Se-GPx to 35 -+ 4, 2.9 -- 0.2 nnitslmg 
protein, and 38 + 2 millianits/mg protein, respectively. Catalase 
activity was not affected by the treatments. These results suggest 
that ACE inhibitors may protect cell components from oxidative 
damage by increasing the enzymatic antioxidant defenses. 
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1. Introduction 
In previous work, we found that mice chronically treated 
with enalapril, a non-sulfhydryl containing ACE inhibitor, 
showed a reduction in myocardial and glomerular sclerosis and 
an increase in the number of mitochondria in myocardiocytes 
and hepatocytes, which was correlated with an increase in their 
survival, when compared with untreated controls [16]. Consid- 
ering that it has been widely postulated that ROS are causally 
involved in the aging process, we hypothesized that enalapril 
might have altered the prooxidant/antioxidant balance, in favor 
of the latter, protecting cells from oxidative damage. The un- 
derlying mechanisms may comprise ither free radical scaven- 
ger properties of enalapril per se, or enalapril-mediated n- 
hancement of antioxidant defenses. Efforts to demonstrate he 
potential ability of this ACE inhibitor to trap free radicals have 
generated conflicting results [17 22]. To study the possibility 
that the effect of enalapril could rely upon its ability to enhance 
antioxidant enzymatic defenses, we measured the activities of 
CuZn-SOD, Mn-SOD, catalase, and Se-dependent glutathione 
peroxidase (Se-GPx) in the liver of mice chronically treated 
with enalapril or captopril. An increased activity of both CuZn- 
SOD, Mn-SOD and of Se-GPx was observed in the liver of mice 
treated during 11 weeks either with captopril or enalapril. 
Superoxide dismutases (SOD), catalase and glutathione per- 
oxidases (GPx) are the main antioxidant enzymes found in 
aerobic organisms, and they constitute part of the physiological 
defenses against oxidative stress [1]. Several evidences indicate 
that an adequate balance among the antioxidant enzymes is 
necessary to minimize the toxic effects of reactive oxygen spe- 
cies (ROS) [2-4]. Moreover, it was recently shown that the 
simultaneous induction of several antioxidant defenses, enzy- 
matic and non-enzymatic, is necessary to increase the mean 
life-span of frogs [5]. 
Angiotensin converting enzyme (ACE) inhibitors, frequently 
used in the treatment of arterial hypertension and cardiac fail- 
ure, have been shown to possess other pharmacological effects. 
They have been shown to decrease myocardial sclerosis in dif- 
ferent pathological situations [6,7], attenuate post-ischemic my- 
ocardial dysfunction [8,9], reduce glomerulosclerosis in diverse 
experimental models [10, 11], and diminish age-related renal 
interstitial fibrosis [12]. The mechanisms underlying those ob- 
servations are not well understood. They may include hemody- 
namic effects, and/or the stimulation of the synthesis of cy- 
toprotective prostaglandins [8,9]. A free radical scavenger 
action has also been postulated [13-15]. 
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2. Materials and methods 
All reagents, enzymes and enzyme substrates were reagent grade and 
were obtained from Sigma Chemical Company (Saint Louis, MO). 
Female CF-1 mice, 4 months old, were randomly separated into 
3 groups that were administered ither tap water (controls) or water 
containing 20 mg/l enalapril maleate (Merck, Sharp & Dohme, West 
Point, PA), or 50 rag/1 captopril (Bristol-Myers Squibb, Princeton, NJ), 
for 4-11 weeks. The doses were chosen according to Ferder et al. [16]. 
Mice received captopril at a higher dose than enalapril due to the 
shorter half-life of that compound. Animals had free access to a Purina 
type I diet (Cargill, Buenos Aires, Argentina). Water consumption was 
determined daily. Body weight and blood pressure were determined by 
tail plethysmography 1 or 2 days before killing. 
At the end of each treatment period (4, 7, 9, and 11 weeks), mice were 
anesthetized with chloroform and the livers were excised after perfusion 
with 150 mM NaC1 at 4°C. For enzymatic determinations, the livers 
were homogenized in 10 vol of 120 mM KC|, 30 mM potassium phos- 
phate, pH 7.4, and centrifuged at600 x g for 10 min. Enzyme activities 
were measured in the supernatant. Protein content was determined 
using bovine serum albumin as standard [23]. 
Total SOD activity was determined following spectrophotometrically 
the inhibition of cytochrome c reduction by superoxide anion at 550 nm 
[24]. One unit of SOD was defined as the amount of enzyme necessary 
to cause a 50% of inhibition of the reduction of cytochrome c (20 pM) 
by superoxide anion generated by the xanthine (50 ktM)/xanthine oxi- 
dase (5 nM) system. To determine Mn-SOD activity, CuZn-SOD was 
wholly inhibited (100%) with 1 mM NaCN. CuZn-SOD activity was 
calculated by subtracting Mn-SOD from total SOD activity. Catalase 
activity, was determined by measuring the decrease in the absorbance 
at 240 nm in a reaction medium containing 50 mM potassium phos- 
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phate buffer, pH 7.0, and 10 mM H202, and calculating the reaction 
constant of pseudo-first order (k') from the decrease in the absorbance 
of H202 (E240 = 40 M -Z" cm-1). Catalase content was expressed as pmol 
catalase/mg of protein, using k = 4.6 x l07 M -j .s -l [1]. Se-GPx was 
determined according to Gfinzler [25] with modifications, by following 
NADPH oxidation at 340 nm. Homogenate samples were incubated in
the presence of 5 mM GSH, 0.5 mM NADPH, 1 mM NAN3, 0.125 U/ml 
glutathione r ductase, and 0.5 mM H202, in 50 mM potassium phos- 
phate, pH 7.7. One unit Se-GPx was defined as the amount of enzyme 
that oxidized one/lmol of NADPH/min at room temperature. 
Statistical analyses were performed using the routines available in 
Statview SE + Graphics v 1.03 (Abacus Concepts, Inc., Berkeley, CA). 
3. Results 
A non-significant increase in body weight was observed in 
the mice treated with either enalapril or captopril as compared 
to controls. At the beginning of treatment, body weights were 
14.6 + 1.3, 15.4 + 1.2, 14.0 + 1.4 g, for control, enalapril- and 
captopril-treated mice, respectively. After 11 weeks of treat- 
ment, the corresponding values were 18.2 + 1.8, 21.3 + 1.5 and 
21.5 + 1.4 g. Similar water intake (16 + 2 ml/d) was observed 
for the three experimental groups throughout the study. Enala- 
pril and captopril had no effect on either liver weight (2.8 _+ 0.2 
g), liver protein content (117 + 5 mg/g liver) or mice blood 
pressure after 11 weeks of treatment (systolic: 112 + 1.3 mmHg, 
n = 7; diastolic: 81 _+ 1 mmHg, n = 7, at week 11). 
The activities of liver CuZn-SOD, Mn-SOD, Se-GPx, and 
catalase in the control mice were not modified throughout the 
treatment period (4 to 11 weeks), (Tables 1-3). Enalapril in- 
creased the activity of CuZn-SOD, Mn-SOD, and Se-GPx after 
9 weeks of treatment, with a maximal effect at week 11. At week 
11 the activities of CuZn-SOD, Mn-SOD, and Se-GPx in the 
livers from enalapril-treated mice were higher (142, 81, and 
100%, respectively) compared to controls (Tables 1-3). Cap- 
topril also increased the activity of the antioxidant enzymes, but 
the effect was observed earlier during treatment. At week 4 the 
activities of liver CuZn-SOD and Se-GPx were significantly 
increased (48 and 61%, respectively) compared to controls. The 
activity of these enzymes remained unchanged until the end of 
the treatment (11 weeks). A significant effect of captopril on 
Mn-SOD was only noticeable at week 11, reaching an increase 
of 38% over the control value (P < 0.05) (Table 2). 
To characterize the possible effect of acute captopril treat- 
ment on the antioxidant enzyme activities, a group of six mice 
was treated uring two days with the ACE inhibitor. The activ- 
ities of liver CuZn-SOD, Mn-SOD, and Se-GPx from the 
treated mice were not different han control values (data not 
shown). 
Table 1 
CuZn-superoxide ismutase activity in liver from mice treated with 
enalapril or captopril 
Treatment CuZn-SOD activity (units/rag protein) 
Time of treatment (weeks) 
4 7 9 11 
Control 21 + 2 (6) 21 + 2 (6) 25 _+ 2 (3) 19 + 4 (6) 
Enalapril 24 + 2 (6) 24 _+ 2 (6) 43 _ 5 (3) a'b 46 _+ 7 (5) a,b 
Captopril 31 + 2 (6) b 36 + 3 (7) b n.d. 35 _+ 4 (6) b 
aStatistically different (P < 0.05) from 4 weeks-group under same treat- 
ment; bstatistically different (P < 0.05) from control group at the same 
week of treatment; n.d., not determined. Data are presented as 
mean + S.E.M. The number of animals is shown in parenthesis. 
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Table 2 
Mn-superoxide ismutase activity in liver from mice treated with enal- 
april or captopril 
Treatment Mn-SOD activity (units/mg protein) 
Time of treatment (weeks) 
4 7 9 11 
Control 2.1 + 0.2 (6) 2.3 + 0.3 (6) 2.2 + 0.4 (3) 2.1 + 0.2 (6) 
Enalapril 2.6 + 0.4 (6) 2.1 + 0.3 (6) 3.1 _+ 0.3 (3) a'b 3.8 _+ 0.2 (5) a'b 
Captopril 2.6 _+ 0.2 (6) 2.3 + 0.1 (6) n.d. 2.9 _+ 0.2 (6) a'b 
~Statiscally different (P < 0.05) from 4 weeks-group under same treat- 
ment; bstatistically different (P < 0.05) from control group at the same 
week of treatment; n.d., not determined. Data are presented as 
mean + S.E.M. The number of animals is shown in parenthesis. 
Catalase activity did not vary in the livers of either control, 
enalapril- or captopril-treated mice during the treatment period 
(4-11 weeks). Values were 12.4 + 3.1 (n = 7), 10.8 + 0.4 (n = 5) 
and 10.7 + 1.0.(n = 6) pmol catalase/mg protein, for control, 
enalapril-, and captopril-treated mice respectively, at 4 weeks 
of treatment. After 11 weeks of treatment, he corresponding 
values were 11.8 + 0.3, 10.2 + 1.7 and 10.7 _+ 0.9 pmol catalase/ 
mg protein. 
4. Discussion 
We have previously shown [16], that the reduction in the 
number of mitochondria that occurs with age in mouse hepato- 
cytes and miocardiocytes was prevented by chronic treatment 
with enalapril. In this paper, we show that enalapril and cap- 
topril increase the activities of CuZn-SOD, Mn-SOD, and Se- 
GPx in mouse liver. This increase in antioxidant defenses 
should protect mitochondrial components from oxidative dam- 
age, preventing the decreased mitochondria number that occurs 
with age. 
Antioxidant enzymes have been reported to increase in 
eukaryotic ells by treatments with X- [26] and UV-radiation 
[27], visible light [28], and paraquat [29]. In mammals Mn-SOD 
is induced by diverse agents, whereas CuZn-SOD is a weakly 
inducible enzyme [30]. The protective role of increasing the 
antioxidant defenses was reported in several systems. In a 
model of cardiac ischemia-reperfusion theaugmentation f the 
activities of total SOD and Se-GPx protects from reactive oxy- 
gen species-mediated injury [311. SOD and catalase ex- 
ogenously administered, reduce the cellular lesions caused by 
myocardial ischemia-reperfusion n dogs [32]. Ldpez-Torres et 
al. found that enhanced levels of CuZn-SOD, glutathione re- 
ductase, glutathione and ascorbate, are correlated with higher 
survival of catalase-inhibited frogs [5]. It has been recently 
reported that the simultaneous overexpression of CuZn-SOD 
and catalase diminishes oxidative stress and increases maxi- 
mum life-span in Drosophila melanogaster [33]. The increase in 
the activities of the antioxidant enzymes may be one of the 
mechanisms responsible for the protective ffects shown by 
ACE inhibitors in vivo in different pathologies [6-12]. 
Interestingly, enalapril and captopril treatments increased 
both the activities of SOD and Se-GPx, but the activity of 
catalase remained unchanged. The coordinate action of SOD, 
catalase and/or GPx appear to be necessary to avoid the forma- 
tion of the highly damaging hydroxyl radical [3,4]. Se-GPx is 
localized in the cytoplasm and in the mitochondria. Thus, the 
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Table 3 
Glutathione peroxidase activity in liver from mice treated with enalapril 
or captopril 
Treatment Se-GPx activity (milliunits/mg protein) 
Time of treatment (weeks) 
4 7 9 11 
Control 28 + 2 (6) 34 + 2 (6) 36 + 4 (2) 27 _+ 3 (7) 
Enalapril 32 + 3 (6) 26 + 4 (6) 58 + 3 (3) a'b 54 + 3 (5) "'b 
Captopril 45 + 3 (6) b 36 + 5 (6) n.d. 38 + 2 (6) b 
"Statistically different (P < 0.05) from 4 weeks-group under same treat- 
ment; bstatistically different (P < 0.05) from control group at the same 
week of treatment; n.d., not determined. Data are presented as 
mean + S.E.M. The number of animals is shown in parenthesis. 
observed increase in Se-GPx activity could counteract for the 
increased production of H202 that might be produced by the 
rise in the activities of cytosolic CuZn-SOD and mitochondrial 
Mn-SOD. 
The mechanism(s) by which the ACE inhibitors could in- 
crease the antioxidant enzymes activities are unknown. The 
doses of enalapril or captopril used in this study did not modify 
arterial pressure. Consequently, it is improbable that variations 
in arterial pressure or in organ hemodynamics play a role in the 
present results. Moreover, considering that the liver does not 
usually respond to changes in arterial pressure or undergo 
hemodynamic variations, it is more likely that the increase 
in the activities of the antioxidant enzymes could be due to: 
(a) a direct effect of the ACE inhibitors on enzyme synthesis 
or activity; (b) a secondary effect resulting from the conse- 
quences of ACE metabolic actions: inhibition of angiotensin II 
synthesis, inhibition ofaldosterone formation and release, stim- 
ulation of renin production, increased cellular sensitivity to 
catecholamines, potentiation of bradykinins, etc. The present 
study does not allow to underscore any of these possibilities. 
Recently, low molecular weight peptides which modify plasma 
and erythrocyte SOD activity were isolated from human 
plasma [32]. Considering that enalapril and captopril are pep- 
tide analogs, they could modify the activities of SOD and Se- 
GPx through a mechanism similar to that of the regulatory low 
molecular weight peptides found in plasma. 
The present results suggests that by increasing enzymatic 
antioxidant defenses, ACE inhibitors may protect cell compo- 
nents from ROS-mediated amage. This effect could afford a 
biochemical mechanism to explain the ACE inhibitors benefi- 
cial actions observed in several degenerative diseases. 
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